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Abstract
Background: Missing data due to attrition are rampant in substance abuse clinical trials. However,
missing data are often ignored in the presentation of substance abuse clinical trials. This paper
demonstrates missing data methods which may be used for hypothesis testing.
Methods: Methods involving stratifying and weighting individuals based on missing data pattern are
shown to produce tests that are robust to missing data mechanisms in terms of Type I error and
power. In this article, we describe several methods of combining data that may be used for testing
hypotheses of the treatment effect. Furthermore, illustrations of each test's Type I error and power
under different missing data percentages and mechanisms are quantified using a Monte-Carlo
simulation study.
Results: Type I error rates were similar for each method, while powers depended on missing data
assumptions. Specifically, power was greatest for the weighted, compared to un-weighted methods,
especially for greater missing data percentages.
Conclusion: Results of this study as well as extant literature demonstrate the need for standards
of design and analysis specific to substance abuse clinical trials. Given the known substantial attrition
rates and concern for the missing data mechanism in substance abuse clinical trials, investigators
need to incorporate missing data methods a priori. That is, missing data methods should be
specified at the outset of the study and not after the data have been collected.
Background
Treatment delivery for substance abuse has evolved from
inpatient care to intensive outpatient care [1]. Although
outpatient settings have increased the population of par-
ticipants able to receive treatment, attrition is substantial
in outpatient substance abuse treatment settings. Recent
studies of substance abuse treatment clinical trials dem-
onstrate considerable drop-out after first dose of treat-
ment [2-6].
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The high percentage of study participant attrition docu-
mented in substance abuse research interferes with the
effectiveness of treatment programs and calls into ques-
tion the validity of study analyses. Furthermore, poor out-
comes are associated poor treatment retention [7].
Although missing data are rampant, it is often ignored in
the presentation of clinical trials [4,8] and statistical
methods of longitudinal data analysis often used in the
substance abuse literature, such as data deletion or single
imputation, may be biased or otherwise invalidated in the
presence of substantial missing data and/or when missing
data that is not missing completely at random [8]. This is
particularly true in substance abuse clinical trials where
missing data in outcomes at a particular point in time may
be dependent upon previous outcomes. For example, a
participant is likely to drop out of a substance abuse treat-
ment clinical trial at the time of relapse.
The statistical literature details many methods of longitu-
dinal data analysis that handle missing data; many have
demonstrated robustness to assumptions of the missing
data mechanism. These methods include, but are not lim-
ited to, multiple imputation [9,10], pattern mixture mod-
els [11], selection models and stratified summary statistics
(SSS) [12-16]. This article describes one of the methods,
SSS, which may be used specifically for hypothesis testing
of the treatment effect.
We first provide an overview of summary statistic and SSS
methods. Next, we discuss modification and expansion of
the SSS method using some of the methods often used in
the statistical literature for data combination. Compari-
sons of these methods are made under different assump-
tions for the missing data – both mechanism and rate of
attrition. Finally, we conclude by describing some of the
strengths and limitations of SSS methods.
Summary Statistic Methods of Longitudinal Data Analysis 
and Missing Data
The summary statistic method of longitudinal data analy-
sis is a technique by which each participant's multivariate
outcome is reduced to a scalar summary measure. Com-
parisons of the scalar summary measures between treat-
ments may then be analyzed using a variety of univariate
statistical techniques [12,15,17-19]. For example, a sum-
mary statistic (e.g. mean, slope) is calculated for each indi-
vidual over time. Then the average summary statistic
response for each treatment group is calculated and com-
pared using an independent t-test.
As with any type of longitudinal data analysis, the sum-
mary statistic approach may need to be modified for
losses to follow-up. Dawson and Han [14] studied the
effect of missing data mechanism on summary statistics.
For example, when the slope is used as a summary statistic
and the missing data mechanism is considered to be com-
pletely random (MCAR) the variance of the slopes varies
dependent on the amount of outcome data available [14].
However, if the missing data mechanism is missing at ran-
dom or nonignorable (MNAR) and/or the trend is nonlin-
ear then the mean of the slopes may vary dependent upon
the amount of information available per individual.
If the missing data patterns differ between treatment arms,
the summary test statistic approach may be invalid [20]. A
method proposed by Dawson [12-16] may be applied to
a variety of summary statistics whereby each participant's
summary response is stratified according to their missing
data pattern. This method is called Stratified Summary
Statistic (SSS) as one stratifies the analysis according to
missingness patterns. This 'stratification by missingness
pattern' may be appropriate when the mean and/or vari-
ance of the summary statistic is dependent upon the
amount or timing of the outcome [12-16].
The computation of SSS as described by Dawson [13] is
detailed below.
Stratified Summary Statistic Calculations
(1) Define an appropriate scalar measure (summary statis-
tic) of the multivariate outcome (e.g. slope, mean,) and
compute the summary statistic for each individual over
time. For example, when an outcome is expected to line-
arly increase or decrease over time, a slope may be a good
selection of a summary statistic [13]. Statistically, the
slopes,  Ssj may be calculated for each participant over
time, s = 1,..., t in each treatment group, j = 1, 2.
(2) Stratify participant slopes by the missing data pattern;
slopes are stratified by the timing of each participant's
dropout, s = 1,..., t. For example, slopes in which subjects
had two observations over time will be placed in one stra-
tum; whereas, slopes in which subjects had three observa-
tions over time will be placed in a separate stratum, etc
(3) Compute stratum-specific test statistics, e.g., a t-test
comparing average treatment differences. Suppose that
the null hypothesis of interest is to test whether the distri-
bution functions of Ss1 and Ss2 are equal, Ho: Fs1 (s) = Fs2
(s). Once slopes are calculated for each individual in each
treatment arm, a stratum specific t-test may be defined
where independent observations are available and their
sizes are ns1 for Ss1 and ns2 for Ss2. Assuming that that the
distributions of Fs1 (s) and Fs2 (s) are normally distributed
with equal variance, σ2, the random variableSubstance Abuse Treatment, Prevention, and Policy 2008, 3:13 http://www.substanceabusepolicy.com/content/3/1/13
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 has a t-distribution
with ns1 + ns2 - 2 degrees of freedom.
(4) Weight each stratum-specific test statistic by the
amount of data available. Dawson proposes a weight that
will increase with the number of participants, ns1 and ns2,
within stratum and with the number of observations per
person in a given stratum, gs [13].
For example, Table 1 demonstrates the number of subjects
in each treatment arm for each stratum, where strata are
defined by the number of visits each subject accumulates
until dropout occurs (for this particular example, 22 sub-
jects had 1 visit before drop-out, 17 subjects had 2 visits
before drop-out, etc.). A weight for stratum 4 would be
computed as
.
Whereas, a weight for stratum 8 is computed as
. The weight for stratum 8 is
greater than that of stratum 4 because stratum 8 consists
of a greater number of subjects (78 versus 20) as well as a
larger number of longitudinal time points (8 versus 4) per
subject until drop-out.
(5) Combine weighted test statistics into an aggregate sta-
tistic (Dawson, 1994).
The aggregate statistic in equation (a) is a weighted sum of
the stratum specific test statistics where the weight, ws is
defined in Step 4 and the test statistic, ts is defined in Step
3. This aggregate statistic is then compared to a standard
normal distribution [12].
Modified SSS
The SSS aggregate statistic as contributed by Dawson [13]
may need to be slightly modified when a t-test rather than
a z-test is chosen for the stratum specific test. That is, the
aggregate statistic may need to adjust for the degrees of
freedom for each stratum specific t-test. One modification
of SSS is to multiply each stratum specific t-test by the
inverse variance of the linear combination of the t-test sta-
tistics.
Then the aggregate statistic is:
The variable vs is the number of degrees of freedom asso-
ciated with each stratum specific t-test statistic.
Fisher's Combination of Probabilities from Independent 
Tests of Significance
The stratified summary statistic procedures described
above are an example of combining independent test sta-
tistics. The statistical literature has supported many meth-
ods of combining independent data and includes
combining estimates, test statistics or p-values [12,21-26].
A popular method for combining one-sided p-values was
proposed by Fisher in 1950 which defines the following
test statistic
where ps is the p-value for each stratum, s = 1,..., t. The test
statistic is then compared to a chi-square with 2t degrees
of freedom.
The sum of s = 1,..., t independent random variables where
each variable has a chi-square distribution is also a ran-
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Table 1: Example of Subject Stratification for SSS, Rows Indicate 
the Treatment Arms, Columns Indicate Strata and Cell Values 
Indicate the Number of Participant
Strata
Treatment 1 2 4 5 8
Placebo 10 7 15 14 38
Drug 12 10 5 14 40
T o t a l 2 21 72 02 87 8Substance Abuse Treatment, Prevention, and Policy 2008, 3:13 http://www.substanceabusepolicy.com/content/3/1/13
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dom variable that is distributed chi-square. The 'degrees of
freedom' for the summed random variable is calculated
by summing the degrees of freedom of each of the s inde-
pendent random variables. Using equation c, let
 where TS is distributed  . Given TS are inde-
pendent:  . In order to combine data using
Fisher's method, p-values must be one sided. Two sided p-
values may be divided by two. Without loss of generality,
the Fisher's approach would always use P(T > t*) [22].
Fisher's statistic has the advantage over Dawson's SSS in
that the combined p-values will follow a chi-square distri-
bution. Combinations of test statistics will depend upon
the distribution of the test-statistics themselves, for exam-
ple when combining t-test statistics the test may need to
be modified to account for the degrees of freedom associ-
ated with each test as demonstrated above.
The Z Transformation Test and the Weighted Z Test
One disadvantage of the Fisher test is an asymmetrical
transformation of p-values making it sensitive to data that
reject the common null in contrast to data which support
the null [24]. The z-transform test does not have this sen-
sitivity [24]. The test transforms (one to one) the one-
sided p-values from independent tests (s = 1,..., t) into a z-
value, zs, from the standard normal distribution. The fol-
lowing statistic is then derived from the s, z-values
Under the null hypothesis, the test statistic is then com-
pared to a standard normal distribution.
Furthermore, the Z-transformation test may be weighted
according to the power of each individual test [25]. This
weighted Z method has the following test statistic
If each test has equal power and is given an equal weight,
then the weighted z-transform test reduces to the z-trans-
form test. A proposed ws for the test includes weights that
are proportional to the inverse of the error variance of
each test [25]. If t-tests are used then proposed weights are
the degrees of freedom for each t-test, i.e. ws = vs [25].
The standard normal deviate, zs, corresponds to each one
tailed p-value, ps. Also, the zs will have the same sign if the
effects are in the same direction but different signs if
effects are in opposite directions. That is, each zs should
have the same sign as the corresponding t-value for each
test [24,25]. Once the normal deviates are computed and
combined the resulting p-value of the aggregate test may
be converted to either one or two sided.
Methods
A Monte Carlo study incorporating the general design of
outpatient substance abuse clinical trials was used to
assess the Type I error and power of hypothesis tests of the
treatment effect. Assumptions of the simulated dataset
were as follows: outcome is assumed to follow a multivar-
iate normal distribution and within unit (subject) varia-
tion was assumed to follow a compound symmetry
structure. A common correlation coefficient of 0.6 was
estimated from the complete cases of previous substance
abuse clinical trials [27]. Outcome was assumed to follow
a linear trend, with participants in both treatments groups
having similar outcome at the beginning of the study and
then decreasing over time. For simulations of Type I error
we let Fplacebo (y) = Ftreatment (y). Data was simulated as mul-
tivariate normal with mean vector [17 16 15 14 13 12 11
10] and σ (yj) = 20 for j = 1,..., 8. For simulations of power
we let Fplacebo (y) ≠ Ftreatment (y), the treatment effect was
assumed to increase over time, i.e. the mean vector for
treatment arm was set at [17 15.05 13.1 11.15 9.2 7.25 5.3
3.35] such that the power for the SSS analysis was approx-
imately 80%. Since this is a study of longitudinal data
analysis, each participant was assumed to have at least two
measurements. A total sample size of n = 100 was
assessed.
Missing data patterns were assumed monotonic; i.e. each
subject was observed and data was recorded until with-
drawal from the study and those who withdrew were not
observed for the remainder of the study [28]. Missing data
patterns in which subjects miss a visit and are lost thereaf-
ter are described as monotonic [27]. This complete 'loss to
follow-up' gives rise to the probability that the missing
data mechanism is not random and may be dependent
upon observed and unobserved values of the outcome.
Several missing data mechanisms defined by their
dependence on observed and unobserved values of the
outcome have been classified by Rubin [9]. The specific
case of monotonic missing data mechanisms for multivar-
iate/longitudinal data has been further described by
Schafer and Graham [29]. If we assume that the outcome
variable, Yij, can be measured for each individual, i = 1,...,
n at several points in time, j = 1,..., t as defined by the
design of the longitudinal study, missing data that are
classified as missing completely at random (MCAR) are
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independent of any outcome variables and any covariates
of interest. Missing at random [30] means that Yij may be
dependent on any of the outcomes observed until the
time of the missed visit, for j = m, i.e. the missing data are
dependent on outcomes Yi1,..., Yi(m-1). Missing not at ran-
dom (MNAR) means that Yim may be dependent on any
outcome not observed due to missed visits. If m is defined
as the time at which a subject drops out of a study and
does not return, then the missing data may be dependent
on any of the unobserved outcomes, Yim,..., Yit.
Missing data due to withdrawal were tested under three
missing data assumptions; i.e., missing data may be con-
sidered either MCAR, MAR or MNAR with respect to out-
come. In order to simulate the missing data mechanism a
complete data set was simulated. The probability of drop-
out was assumed to follow a logistic regression model [31-
33] and was used to simulate the missing data in the com-
plete dataset.
For example, missing data that are MAR in a longitudinal
dataset are dependent on outcomes observed prior to the
dropout. If we let the function hk (y1,..., yk) where k = 1,...,(t
- 1) be a covariate in a logistic regression model on the
probability of drop-out we will have the following logit
model: ,  where  α is the
intercept and β is the slope of the logit.
The function hk, can be defined as the latest observed
measurement, i.e. hk (y1,..., yk) = yk. Using the latest obser-
vation in substance abuse trials may have validity since,
much of the drop-out observed may be due to relapse or
no change in response. Therefore, observed positive tests
or high levels of cocaine (benzoylecognine) may be pre-
dictive of drop-out and the missing data mechanism can
be classified as MAR. Using this function, the probability
of dropout for each time point may be computed,
. If β = 0, then the missing data mecha-
nism is MCAR.
In order to simulate a 10% missing data percentage with
a MAR missing data mechanism under the null, we set α13
= -106, α14 = -105, α15 = -104, α16 = -103, α17 = -102, α18 =
-101 and β = 2. For a 40% missing data percentage param-
eters were set as follows: α13 = -70, α14 = -69, α15 = -68, α16
= -67, α17 = -65, α18 = -64 and β = 2.
However, if the missing data mechanism is not ignorable
then the logit model for each time point may be defined
as:   where time is
defined j = 1,..., t and time before the last observation is
defined k = 1,..., (t - 1) [31,34]. If γ = 0 for each time point
then the dropout model is MAR; whereas, if γ ≠ 0 for each
time point then the missing data mechanism is MNAR.
That is, unobserved outcome may be predictive of drop-
out and the missing data mechanism may be MNAR.
To simulate a 10% missing data percentage with a MNAR
missing data mechanism under the null, we set α13 = -106,
α14 = -105, α15 = -104, α16 = -103, α17 = -102, α18 = -101, β
= 0 and γ = 2. For a 40% missing data percentage with a
MNAR missing data mechanism parameters were set as
follows: α13 = -70, α14 = -69, α15 = -68, α16 = -67, α17 = -65,
α18 = -64 β = 0 and γ = 2. In order to simulate 40% missing
data with a combination of MAR and MNAR missing data
mechanisms, we set α13 = -105, α14 = -104, α15 = -103, α16
= -102, α17 = -101, α18 = -100 β = 2 and γ = 2.
Two thousand simulations were preformed for each
method for missing data percentages of 10% and 40%
and missing mechanisms of MCAR, MAR, a combination
of both MAR and MNAR, and MNAR. To meet the stand-
ards of computation-based analysis, the optimal number
of simulations was calculated using the coverage probabil-
ity of 95% around the estimated Type I error probability
of .05 [35]. Using this method, the simulation sample size
was approximately 2,000. This simulation size also results
in both Type I error estimates and power estimates which
had standard errors less than or equal to .01.
Several methods of combining independent data were
used to analyze each data set. Specifically, participants
were stratified into mutually exclusive missingness catego-
ries. Stratum specific independent t-tests were computed
using slope means for each treatment arm. Each t-statistic
or p-value was weighted. Stratum specific t-statistics or p-
values were then combined into an aggregate statistic and
compared to the standard normal distribution. Empirical
size and power for each method of analysis was compared
over 2000 simulations.
Choice of Weights
For a t-test, power should be maximized when ws is pro-
portional to the noncentrality parameter of the distribu-
tion of each stratified test statistic, Zs, for a given model
[12,16,36]. A general weight that is proportional to the
non-centrality parameter is  .
A variety of weights may be chosen to increase the power
of the test. Estimates of population weights may also be
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utilized [11]. The population weights for each stratum can
be defined:  , where  . The population
weights will weight the t-tests produced from a larger pro-
portion of the sample heavier than those with smaller
sample size. Choice of weights will affect the power of the
test, any weight that weights a more efficient estimate
heavier than a less efficient estimate will produce a more
powerful test.
Another weight may incorporate the Sum of Squares for
Time. Generally t-tests are uniformly most powerful tests;
however, the t-tests do not incorporate the efficiency gain
by measuring participants over a number of longitudinal
time points. One way to improve efficiency may be to
weight each t-test by the source of variation due to time.
The Sum of Squares for time may be calculated,
 for each stratum and used to
weight each t-test.
Results
Overall the results demonstrate nominal Type I error
probabilities for Fisher's Method, the Weighted Z-Trans-
form Test and Modified SSS compared to SSS (using stra-
tum specific t-tests) under a variety of assumptions.
However, SSS produced larger Type I errors compared to
the other methods. Further, the modified SSS which cor-
rects for the degrees of freedom associated with the t-tests
produced tests of nominal size. Type I error probabilities
showed little variation for a 10% missing rate compared
to a 40% missing rate.
Table 2 demonstrates the Type I error probability under a
variety of missing data percentages (10% and 40%) and
mechanisms (MCAR, MAR, a combination of MAR and
MNAR as well as MNAR) for all methods. Simulations for
this particular table assumed a small sample size of 100, a
common correlation coefficient of .6 and a simulation
number of 2000. For all conditions, the Type I error prob-
abilities of SSS are larger than those of the other methods
compared. The Fisher method produces the most conserv-
ative results in terms of Type I Error; however, the differ-
ences are negligible. Finally, little variation is observed in
the Type I error probabilities between the different miss-
ing data percentages and/or mechanisms.
Power for each test differed dependent on the method
used as well as the missing data percentage and mecha-
nism assumed. Table 3 demonstrates the power under a
variety of missing data percentages (10% and 40%) and
mechanisms (MCAR, MAR, a combination of MAR and
MNAR as well as MNAR) for all methods. Simulations for
this particular table assumed a small sample size of 100, a
common correlation coefficient of .6 and a simulation
number of 2000. Results for Table 2 demonstrate that
power was generally greater for SSS compared to all other
methods; however, this may be due to the inflated Type I
error probabilities as previously discussed. Power was
comparable across methods for the 10% missing data per-
centage. However, Fisher's method demonstrated a reduc-
tion in power for the 40% missing data percentage
compared to modified SSS and the Weighted Z-Transform
Test. Second only to SSS, the weighted Z-transform test
demonstrated robustness in power for all missing data
percentages and mechanisms.
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Table 2: Type I Error Probabilities of Methods for Missing Data Percentages (10% and 40%) and Mechanisms
Method Missing Percentage MCAR MAR MAR/MNAR MNAR
SSSa 10% 0.0920 0.0895 0.0875 0.0895
40% 0.0945 0.1035 0.1050 0.1115
Modified SSSb (Dawson Weight) 10% 0.0615 0.0580 0.0580 0.0585
40% 0.0525 0.0520 0.0495 0.0555
Modified SSSb (Population Weight) 10% 0.0600 0.0585 0.0585 0.0585
40% 0.0535 0.0520 0.0535 0.0540
Modified SSSb (SSTime Weight) 10% 0.0615 0.0590 0.0575 0.0590
40% 0.0540 0.0535 0.0575 0.0525
Fisherc 10% 0.0495 0.0555 0.0495 0.0510
40% 0.0495 0.0445 0.0505 0.0460
Weighted Z-Transformd 10% 0.0575 0.0595 0.0580 0.0570
40% 0.0545 0.0550 0.0525 0.0530
*Type I error, r = .6, n = 100, simulations = 2000
*a, b, c, d indicate the methods of analysis in the textSubstance Abuse Treatment, Prevention, and Policy 2008, 3:13 http://www.substanceabusepolicy.com/content/3/1/13
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For all methods, power is decreased at least 35% for a
missing data percentage of 10% versus 40%. Power is dra-
matically decreased for the Fisher method given a missing
data percentage of 40% and a missing data mechanism of
MAR or MNAR. In general, power fluctuations are
observed for each missing data mechanism.
Conclusion
The statistical literature has an abundance of methods of
analysis for longitudinal datasets with missing data. This
paper focuses on missing data methods which can be used
for hypothesis tests of the treatment effect when the miss-
ing data pattern is monotonic. Specifically, Dawson's
stratified summary statistic and several other methods of
combining data were assessed and developed for analysis
with missing data due to their robustness to the missing
data mechanism. That is, stratifying data by the missing
data pattern, computing stratum specific statistics and
aggregating these statistics produces tests which have
nominal Type I Error and optimal power even in the pres-
ence of nonignorable missing data [12-16]. These hypoth-
esis tests of the treatment effect which are robust to the
missing data mechanism may be applicable to the analy-
sis of substance abuse clinical trials because missing data
in substance abuse trials are predominately due to relapse
and therefore the missing data may be nonignorable or
dependent upon previous outcomes.
In this article, we have focused on two missing data per-
centages, a 10% rate and a 40% rate, with each treatment
arm having similar amounts of missing data. In many
clinical trials, the missing data percentage and/or mecha-
nism may vary across treatment arm. Shih and Quan (21)
demonstrate that Type I Error may be inflated when the
missing data percentage differs between treatment arm
and the missing data mechanism is MAR. Further simula-
tion studies may want to focus on these variations and
their effects on the Type I Error and power of hypothesis
tests of the treatment effect.
This article demonstrates the impact that attrition can
have on some of the statistical methods which are used for
longitudinal data analysis. It should be noted that analy-
sis should not be limited to these methods. These meth-
ods focus on testing hypotheses of the treatment effect. If
the focus of a trial is on parameter estimation, a modeling
approach of the missing data such as a pattern mixture or
selection model may be more appropriate [11].
Furthermore, the stratified summary statistic methods
possess a 'post hoc' quality. That is, we stratify on the pat-
tern of missing data, which is not known until the data
have been collected. In statistics we propose separation of
the design from the analysis, i.e. the study design and
analysis are specified in advance of data collection.
Although we will not know the exact pattern of missing
data until all subject outcomes have been collected, it is
well-known that substance abuse clinical trials are prone
to high rates of attrition. Therefore, the use of missing data
methods may be planned in advance of the study and may
be specified in the study protocol. Furthermore, any
reports of results from these analyses should be tempered
with the knowledge that the analysis was dependent on
the missing data pattern, which could not be fully dis-
cerned a priori.
The weighting schemes used in this paper are 'precision-
based', and they weight stratum statistics with a larger
amount of participants and/or more time point more
than those with less. These methods seem to suggest that
'treatment works for those who work for it'. That is, we are
weighting those subjects who perform better in the clini-
cal trial more than those who perform worse (those that
Table 3: Power of Methods for Missing Data Percentages (10% and 40%) and Mechanisms
Method Missing Rate MCAR MAR MAR/MNAR MNAR
SSSa 10% 0.8370 0.9355 0.9225 0.9355
40% 0.5705 0.6125 0.5750 0.5600
Modified SSSb (Dawson Weight) 10% 0.8165 0.9000 0.8810 0.8970
40% 0.4445 0.3755 0.3660 0.3000
Modified SSSb (Population Weight) 10% 0.8240 0.9075 0.8910 0.9075
40% 0.4990 0.4150 0.4105 0.3850
Modified SSSb (SSTime Weight) 10% 0.8220 0.8675 0.8820 0.8990
40% 0.4770 0.3075 0.3795 0.3780
Fisherc 10% 0.7655 0.6940 0.6710 0.6855
40% 0.3240 0.1505 0.1460 0.1195
Weighted Z-Transformd 10% 0.8265 0.9080 0.8965 0.9085
40% 0.4990 0.4440 0.4355 0.4130
*Power, r = .6, n = 100, simulations = 2000
*a, b, c, d indicate the methods of analysis in the textSubstance Abuse Treatment, Prevention, and Policy 2008, 3:13 http://www.substanceabusepolicy.com/content/3/1/13
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tend to drop-out due to relapse). However, these methods
are preferred to 'complete case' analysis which drops sub-
jects with any missing data. Also, results from this simula-
tion study and several other studies demonstrate that
these methods are robust to the missing data mechanism
in terms of hypothesis testing of the treatment effect [12-
16].
Further studies should investigate the robustness in Type
I error and power of stratified summary statistics as well as
bias and precision of the estimates of the treatment effect
for these methods. Also, future studies may want to use
other weighting schemes including 'bias-based' weights
[37]. However, use of bias-based weights would need to
be justified a priori by determining the cause and direc-
tion of the bias incurred due to attrition in substance
abuse clinical trials. Given the known history of attrition
in substance abuse clinical trials where much of the attri-
tion may be contributed to relapse; bias based weighting
schemes may be justifiable in this setting.
The simulations for the comparisons of missing data
could also be further generalized. For these particular sim-
ulations, missing data rates were set at 10% and 40%. We
chose a missing data percentage of 40% because of the
known high prevalence of missing data in longitudinal
substance abuse clinical trials [2-6]. However, these meth-
ods can be generalized to more intermediate missing data
percentages in order to demonstrate changes in Type I
error and power with a variety of missing data rates.
No matter how well-designed a clinical trial, these high
attrition rates can bias the analysis of a clinical trial. Valid-
ity in the presence of missing data is often dependent
upon the method of analysis selected. Specifically, inap-
propriate methods may produce hypothesis tests of the
treatment effect without appropriate size and/or power.
Therefore, it is imperative that substance abuse clinical tri-
als prepare for inevitable missing data due to attrition.
That is, this paper demonstrates the need for policy devel-
opment for evidence based practice specific to the analysis
of longitudinal substance abuse clinical trials in the pres-
ence of substantial drop-out. For example, given the wide
variety of methods used for analysis of substance abuse
clinical trials, we may want to specify that missing data
methods be incorporated into the design and analysis
given the unique properties of this research paradigm.
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